Palisade Bio Announces Strategic Equity Investment from the Crohn’s & Colitis Foundation’s IBD Ventures Program to Advance PALI-2108

Core Viewpoint - Palisade Bio, Inc. is advancing PALI-2108, a unique PDE4 inhibitor designed for targeted delivery to the terminal ileum and colon, addressing significant unmet needs in ulcerative colitis (UC) and fibrostenotic Crohn's disease (FSCD) [1][2] Investment and Support - The Crohn's & Colitis Foundation has approved a strategic equity investment of up to $500,000 in Palisade to support the clinical development of PALI-2108 [1][2] - This investment is seen as a strong endorsement of the scientific rationale behind PALI-2108 and its targeted approach to PDE4 inhibition [2] Clinical Development - Palisade has completed several studies, including a Phase 1a and Phase 1b cohort study in UC, and is currently evaluating PALI-2108 in an ongoing Phase 1b cohort study in FSCD [1][3] - Data from these studies are expected to support Phase 2 Investigational New Drug (IND) submissions to the FDA in 2026 [1] Product Characteristics - PALI-2108 is an orally administered prodrug that is gut-restricted and pharmacologically inactive until it reaches the lower intestine, where it is activated by bacterial enzymes [3] - The design allows for sustained local exposure, longer half-life, and once-daily dosing, aiming to maximize anti-inflammatory effects while minimizing systemic exposure [3] Clinical Efficacy - In a recent Phase 1b trial, PALI-2108 achieved a 100% clinical response in the UC cohort, with no serious adverse events reported [7] - The company is preparing for a Phase 2 clinical study in UC to evaluate clinical remission and response over 12 weeks [8]